With the publication of AIFA Determination No. 966/2025, new criteria are introduced for the classification of innovative medicines and anti‑infective agents intended for the treatment of infections caused by multidrug‑resistant organisms.
Here is a focus that analyses the main new elements and highlights the differences compared with the first proposal released by the Italian Medicines Agency, offering a clear and up‑to‑date overview for healthcare professionals, institutions and sector stakeholders.
